A quick guide to U.S. and global operations. | Overview: | Daiichi Sankyo, Inc., is the U.S. headquarters of Tokyo-based DAIICHI SANKYO, COMPANY, LTD. Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group, which spans 56 countries. Click here to download an easy-to-read company overview. | | Established: | Daiichi Sankyo, Inc. was established in 2006 from the merger of the Daiichi and Sankyo pharmaceutical companies. | | Industry: | Pharmaceuticals | | Concentration: | We currently market therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome and metastatic melanoma. | | U.S. Headquarters: | Daiichi Sankyo, Inc.
Two Hilton Court
Parsippany, NJ 07054
Phone: 973-944-2600 | | President and CEO: | John P. Gargiulo | | U.S. Employees: | Approximately 3,000 including Daiichi Sankyo Pharma Development | | FY 2011 Net Sales: | $1.6 Billion | | Global Clinical Development: | Daiichi Sankyo Pharma Development
399 Thornall Street
Edison, NJ 08837
Phone: 732-590-5000 | | Global Head, Research & Development/President | Glenn J. Gormley, M.D., Ph.D.
Also Senior Executive Officer Daiichi Sankyo
President, Daiichi Sankyo Pharma Development (DSPD) | | Parent Company: | DAIICHI SANKYO, COMPANY, LTD. (TSE 4568)
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo
103-8426, Japan
Phone: +81-3-6225-1111
daiichisankyo.com | | European Headquarters: | DAIICHI SANKYO EUROPE, GhbH
Zielstattstrasse 48
81379 Munich, Germany
Phone: +49-89-7808-0
daiichi-sankyo.eu | | Employees Worldwide: | 31,929 employees (as of May 2012) | | Products Marketed in the U.S.: | AZOR® (amlodipine/olmesartan medoxomil)
See full Prescribing Information including Boxed WARNING regarding Fetal Toxicity.
BENICAR® (olmesartan medoxomil)
See full Prescribing Information including Boxed WARNING regarding Fetal Toxicity.
BENICAR HCT® (olmesartan medoxomil/hydrocholorothiazide)
See full Prescribing Information including Boxed WARNING regarding Fetal Toxicity.
EFFIENT® (prasugrel) tablets
See full Prescribing Information including Boxed WARNING regarding Bleeding Risk.
EVOXAC® (cevimeline HCI)
See full Prescribing Information.
TRIBENZOR®
(olmesartan medoxomil/amlodipine/hydrocholorothiazide)
See full Prescribing Information including Boxed WARNING regarding Fetal Toxicity.
WELCHOL® (colesevelam HCI)
See full Prescribing Information.
ZELBORAF® (vemurafenib)
See full Prescribing Information.
| | |
